Antisense Therapeutics Limited
ATHJF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$19.64M
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $19.64 Million |
|---|---|
| Enterprise Value | - |
| Earnings per Share | $-0.01 |
| Beta | 0.87 |
| Outstanding Shares | 1,038,182,810 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Percheron Therapeutics Limited
8 employees
CEO: James Stuart Garner
Percheron Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals for cancer and rare diseases in Australia. The company's lead asset is ATL1102, an antisense oligonucleotide inhibitor of CD49d, wh...